POCone-UBiT-IR300 Pediatric Comparison Study
- Conditions
- Interventions
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 99
- Registration Number
- NCT01623154
- Locations
- ๐บ๐ธ
Miami Pediatric Gastroenterology, Miami, Florida, United States
๐บ๐ธUniversity of Texas School of Public Health, El Paso, Texas, United States
๐บ๐ธBaylor College of Medicine, Houston, Texas, United States
Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia
- Conditions
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 5028
- Registration Number
- NCT01240668
- Locations
- ๐บ๐ธ
North America Research Institute, Azusa, California, United States
๐บ๐ธMemorial Healthcare System, Hollywood, Florida, United States
๐บ๐ธCoastal Nephrology Associates Research, Port Charlotte, Florida, United States
Study for the Treatment of Crohn's Disease With Adacolumn
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 235
- Registration Number
- NCT00162942
- Locations
- ๐บ๐ธ
Medical Research Institute of Connecticut, Hamden, Connecticut, United States
๐บ๐ธDartmouth-Hitchcock Medical Center, Lebanon,, New Hampshire, United States
๐บ๐ธMemphis Gastroenterology Group, Germantown, Tennessee, United States
Study for the Treatment of Ulcerative Colitis With Adacolumn
- Conditions
- First Posted Date
- 2005-01-25
- Last Posted Date
- 2008-09-08
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 168
- Registration Number
- NCT00102193
- Locations
- ๐บ๐ธ
Johns Hopkins Hospital, Baltimore, Maryland, United States
๐จ๐ฆSt. Michael's Hospital, Toronto, Ontario, Canada
๐บ๐ธLong Island Clinical Research Associates, Great Neck, New York, United States
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
- Conditions
- First Posted Date
- 2002-11-11
- Last Posted Date
- 2005-07-19
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 75
- Registration Number
- NCT00048763
- Locations
- ๐บ๐ธ
The Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
๐บ๐ธLaRabida Children's Hospital, Chicago, Illinois, United States
๐บ๐ธAdvanced Medical Clinical Therapeutics, Anchorage, Alaska, United States
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
- Conditions
- First Posted Date
- 2002-11-11
- Last Posted Date
- 2005-07-19
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 75
- Registration Number
- NCT00048776
- Locations
- ๐บ๐ธ
Madera Family Medical Group, Madera, California, United States
๐บ๐ธChildren's Hospital Boston, Boston, Massachusetts, United States
๐บ๐ธSt. Louis University Health Sciences Center, St. Louis, Missouri, United States
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT00002131
- Locations
- ๐บ๐ธ
UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธNorthwestern Univ Med School, Chicago, Illinois, United States
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 56
- Registration Number
- NCT00002337
- Locations
- ๐บ๐ธ
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Otsuka America Pharmaceutical
- Registration Number
- NCT00002130
- Locations
- ๐บ๐ธ
UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธAIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 36
- Registration Number
- NCT00002129
- Locations
- ๐บ๐ธ
UCLA School of Medicine, Los Angeles, California, United States